Table 3: COVID-19 treatment, length of hospitalization and outcomes by race.
|
|
African Americans n = 249 (%) |
Caucasians, n = 135 (%) |
Others, n = 16 (%) |
P-value |
|
COVID-19 treatment |
|
|
|
|
|
Hydroxychloroquine |
115 (46.2) |
50 (37) |
4 (25) |
0.081 |
|
Azithromycin |
138 (55.4) |
60 (44.4) |
7 (43.8) |
0.1 |
|
Convalescent plasma |
6 (2.4) |
8 (5.9) |
2 (12.5) |
0.051 |
|
Included in a study (Remdesivir vs. placebo) |
10 (4) |
1 (0.7) |
2 (12.5) |
0.023 |
|
Steroid |
31 (12.4) |
20 (14.8) |
1 (6.2) |
0.576 |
|
Anti-IL-6 |
8 (3.2) |
2 (1.5) |
0 |
0.471 |
|
IV antibiotics |
|
|
|
|
|
Vancomycin |
56 (22.5) |
33 (24.4) |
3 (18.8) |
0.836 |
|
Piperacillin-tazobactam |
18 (7.2) |
12 (8.9) |
0 |
0.428 |
|
Cefepime |
46 (18.5) |
35 (25.9) |
4 (25) |
0.218 |
|
Metronidazole |
4 (1.6) |
6 (4.4) |
0 |
0.190 |
|
Others |
19 (7.6) |
8 (5.9) |
0 |
0.447 |
|
Outcome |
|
|
|
|
|
Improved or cured |
162 (65.1) |
85 (63) |
11 (68.8) |
0.292 |
|
Worse but discharged |
|
|
|
|
|
Death |
52 (20.9) |
29 (21.5) |
2 (12.5) |
0.225 |
|
Length of hospital stay (Mean ± SD) |
9.67 ± 8.8 |
9.2 ± 7.7 |
13 ± 9.5 |
0.24 |
|
Length of ICU stay (Mean ± SD) |
11.3 ± 10.9 |
8.7 ± 6.6 |
9.9 ± 11 |
0.424 |
IV: Intravenous; ICU: Intensive Care Unit.
Length of hospital stay or ICU stay did not differ among the different races. Among 13 patients who were enrolled in remdesivir study, 10 were African Americans. However, proportion of patients who participated in the remdesivir trial was highest for patients from other races followed by African Americans.